Infectious diseases have long been considered one of the triggers for autoimmune and autoinflammatory diseases. Since the appearance of the new coronavirus in December 2019 in the city of Wuhan, China, there have been many reports suggesting that infection with coronavirus 2 (SARS-CoV-2) precedes the appearance of several autoimmune and autoinflammatory diseases. We describe a case report of a patient who was infected with the SARS-CoV-2 virus and later developed a picture of Hashimoto’s thyroiditis.

We report a case of the use of colchicine in a patient infected with SARS-CoV-2 virus. A 37-year-old man with COVID-19 presented with moderate symptoms, mild pulmonary impairment and elevated inflammatory markers, suggesting an increased risk of cytokine storm and possible worsening of clinical condition. Experimental use of colchicine resulted in an 85% decrease in C reactive protein levels 3 days after treatment initiation and a 182.6% decrease in interleukin-6 levels 8 days after treatment initiation. Due to the lack of effective therapies, it is important to search for potential compounds and compounds that focus on controlling the danger caused by systemic inflammation in COVID-19. Although further research is needed in the area of colchicine and viral infection, preliminary efficacy was observed.

CA 72-4 is a tumor marker associated with gastrointestinal, lung and ovarian tumors. The analysis of tumor markers is not usual in COVID-19, since there is no established relationship between SARS-CoV-2 infection and the development of tumors, but data suggest that 15 percent of all human cancers worldwide may be attributed to viruses. Changes in Ca 72-4 levels were observed in individuals with COVID-19, suggesting a possible oncogenic characteristic of the virus, requiring further attention and investigation. BACKGROUND: Since the arrival of a new type of coronavirus in December 2019 in Wuhan, China, the world has undergone changes due to the pandemic impact caused by the virus. SARS-CoV-2 is mainly related to lung involvement, but gastrointestinal complaints, such as vomiting and diarrhea, have also been reported. METHODS: We brought a series of cases of patients seen in Brazil, infected by SARS-CoV-2, who had high levels of CA 72.4 during the course of the infection, suggesting a possible oncogenic characteristic of the virus under study. RESULTS: The described group showed relevant variations in the levels of the tumor marker CA 74-2 after infection by the SARS-CoV-2 virus. The minor variation of the tumor marker was 4% and the highest observed, 7146%. CONCLUSIONS: Considering that some viruses can induce the tumor process, the analysis of tumor markers after viral infection can be a useful tool in assessing the possible impact on post-pandemic global health scenario.

Introduction: In December 2019, a new type of coronavirus was discovered in Wuhan, China, characterized by a picture of atypical pneumonia composed of fever, dry cough and progressive dyspnea. Autopsy analyzes of patients with Covid-19 were performed, and hyperactivation of cytotoxic T cells was observed, suggesting an increase in humoral-type immunological signaling, where interleukin 6 (IL-6) is a mediator present that can fit as a potential critical agent for exacerbation of inflammatory conditions. In addition, not only interleukin-6, but also serum C-reactive protein (CRP) and ferritin have been recognized as strong predictors of COVID-19 severity. Recent studies have shown that the use of liraglutide has antioxidant and anti-inflammatory effects in vitro. Thus, the present case report discusses the possible anti-inflammatory properties of the antidiabetic drug liraglutide (Saxenda), in Covid-19. Clinical Case: JCMS, 45 years, male, married, obese grade 2 (BMI: 38.2), sought medical service on August 18, 2020, bringing a positive result of the RT-PCR test for Covid-19, performed in last day. The patient was in good general condition, reporting mild headache and adynamia. He was prescribed to start a treatment with Saxenda (6mg/ml - started 0.6mg/day at week 1, with a gradual increase up to 3mg/day at week 5); Jardiance (25mg / day); Fluimicil (600mg); Ivermectin (6mg) and Colchicine (0.5mg every 12 hours). In addition, collection of laboratory tests was requested. Examination results: IL6: <1.5 pg/mL; Ferritin: 819 ng/ml; C-reactive protein: 5.1mg/L. On August 24, the patient was tachycardic (HR 120–140 bpm) associated with headache and fever (38 °C). Azithromycin (500mg), dexamethasone (4mg) and dipyrone (1g) were prescribed. Collection of laboratory tests was requested. Examination results: IL6: 9.3 pg/mL; Ferritin: 1085 ng/ml; C-reactive protein:23.9mg/L. On September 3, the patient was in good general condition, eupneic, afebrile, with no complaints to declare. On September 6, the collection of laboratory tests was requested. Examination results: IL6: <1.5 pg/mL; Ferritin: 687 ng/ml; C-reactive protein: 1.7mg/L. Conclusion: Based on the described report, it is possible to observe a good clinical and laboratory evolution of the patient with Covid-19 who, among the drugs used, made use of liraglutida. Diabetes and obesity are considered significant risk factors for morbidity and mortality by COVID-19, since they are a condition of low-grade chronic inflammation and in these conditions, inflammatory markers such as CRP, IL-6 and ferritin have strong signs of alteration. Thus, the possible beneficial effect of the administration of liraglutide in obese patients is highlighted, as a potential anti-inflammatory effect, especially in the COVID-19 era.

No abstract